Onconova Therapeutics, Inc. (ONTX) Sets New 52-Week Low at $1.50
Onconova Therapeutics, Inc. (NASDAQ:ONTX) reached a new 52-week low during mid-day trading on Thursday . The stock traded as low as $1.50 and last traded at $1.54, with a volume of 99,673 shares traded. The stock had previously closed at $1.55.
Several equities research analysts have issued reports on ONTX shares. Maxim Group set a $6.00 price objective on shares of Onconova Therapeutics and gave the stock a “buy” rating in a research note on Tuesday, August 15th. Dawson James reiterated a “buy” rating on shares of Onconova Therapeutics in a research note on Tuesday, July 25th. Finally, ValuEngine upgraded shares of Onconova Therapeutics from a “strong sell” rating to a “sell” rating in a research note on Friday, September 1st.
The firm’s market capitalization is $15.17 million. The stock has a 50 day moving average of $1.78 and a 200-day moving average of $2.21.
Onconova Therapeutics (NASDAQ:ONTX) last issued its quarterly earnings data on Monday, August 14th. The biopharmaceutical company reported ($0.29) earnings per share for the quarter, beating the consensus estimate of ($0.72) by $0.43. The firm had revenue of $0.32 million for the quarter, compared to analyst estimates of $0.25 million. Onconova Therapeutics had a negative net margin of 762.13% and a negative return on equity of 558.97%. Analysts predict that Onconova Therapeutics, Inc. will post ($2.92) EPS for the current year.
An institutional investor recently raised its position in Onconova Therapeutics stock. Vanguard Group Inc. grew its position in Onconova Therapeutics, Inc. (NASDAQ:ONTX) by 58.4% during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 87,940 shares of the biopharmaceutical company’s stock after purchasing an additional 32,418 shares during the quarter. Vanguard Group Inc. owned approximately 0.93% of Onconova Therapeutics worth $190,000 as of its most recent SEC filing. 26.83% of the stock is currently owned by institutional investors and hedge funds.
Onconova Therapeutics Company Profile
Onconova Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company operates through the identification and development of oncology therapeutics segment. It is focused on discovering and developing small molecule drug candidates to treat cancer. The Company has created a targeted anti-cancer agents designed to work against specific cellular pathways that are important to cancer cells.
Receive News & Ratings for Onconova Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Onconova Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.